Over 800 patients are set to take part in phases II and III of a trial of a COVID-19 treatment based on human monoclonal antibodies.
The monoclonal antibodies were identified by the Mad Lab research team of the Toscana Life Sciences (TLS) foundation coordinated by Rino Rappuoli.
The first phase of trials on 30 healthy volunteers took place at Rome's Spallanzani infectious-diseases hospital and at the Verona Clinical Research Centre.
TLS said the next phases will involve patients infected with Sars-CoV-2.
It said 14 research centres in Rome, Piacenza,Trieste, Pavia, Foggia, Siena, Vercelli, Verona, Milan, Parma, Pisa, Florence, Naples and Avellino will take part.
ALL RIGHTS RESERVED © Copyright ANSA
